ZYBERNO
Stock Report
Updated Aug 21, 2026

Cartesian Therapeutics, Inc. (RNAC)

Healthcare • NASDAQ

$10.24

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
19.0/100
POOR BUSINESS
Cartesian Therapeutics, Inc. (RNAC) scores 19/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-10,518.6%)
Return on Capital (Capital Efficiency):CRITICAL (-68.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Cartesian Therapeutics, Inc. (RNAC) stock report — Zyberno Score 19/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, RNAC generated -$74.69M in Owner Earnings. Capital was deployed as follows: $4.41M invested in capital expenditures. Reinvestment rate: -2.6%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:10.24
Market Cap:$301.74M

Valuation Multiples (2)

P/S Ratio:204.29x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$211.19M

Price Action & Momentum (3)

Momentum Percentile:37 / 100
% of 52-Week High:83.6%
B. Profitability Assessment

Return Metrics (4)

ROA:-47.6%
Reinvestment Rate:-2.6%
Fundamental Growth Rate (g):1.8%

Margin Analysis (3)

Operating Margin Ttm:-10,518.6%
Net Margin Ttm:-10,283.8%
Ebitda Margin:-10,342.5%

TTM Performance (2)

Operating Margin Ttm:-10,518.6%
Net Margin Ttm:-10,283.8%

Yield Metrics (2)

Earnings Yield:-$66.14
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:186.4%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):32.9%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:7.48x
Quick Ratio:7.48x
Cash Ratio:7.18x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-168.32x
Times Interest Earned:-168.32

Capital Structure (4)

Working Capital:133,065,000.00
Cash And Cash Equivalents:147,606,000.00
Long Term Debt:$52.85M
Net Debt:-$90.56M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $1.48M
Linear Growth: -50.0%
📊 Click to view full RNAC Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$155.36M

Bottom Line Performance (3)

Net income TTM: -$151.89M
Linear Growth: 32.9%
📊 Click to view full RNAC Net Income analysis & methodology →
Income Before Tax:-$9.00M
Ebitda Ttm:-152,759,000.00

Operating Expenses (5)

Operating Expenses:156,836,000.00
R And D Expense:68,385,000.00
Sga Expense:31,751,000.00
Income Tax Expense:-$321.00K
Interest Expense:852,000.00

Expense Ratios (1)

Ebitda Margin:-10,342.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$318.63M
Current Assets:$153.62M
Ppe Net:11,311,000.00
Goodwill:48,163,000.00
Intangible Assets:$93.90M

Liability Structure (4)

Total Liabilities:443,854,000.00
Current Liabilities:20,550,000.00
Long Term Debt:$52.85M
Short Term Debt:$4.20M

Equity & Capital (3)

Equity:-$125.23M
Retained Earnings:-$845.79M
Common Stock:350,000,000.00

Working Capital Items (3)

Accounts Receivable:196,000.00
Inventory:0.00
Accounts Payable:15,142,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,083,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$72.97M-$77.37M

Investment Activities (2)

Investing Cash Flow:-$27.00K
Capital Expenditures Ttm:4,406,000.00

Financing Activities (3)

Financing Cash Flow:$15.67M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:15,392,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,600,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-5.84
Eps diluted TTM: -$5.84
Linear Growth: 100.0%
📊 Click to view full RNAC EPS analysis & methodology →
Earnings Per Share Ttm:-$5.15

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.05
Operating Cash Flow Per Share:-$2.51

Book Value & Capital (2)

Book Value Per Share:-$4.25
Cash Per Share:5.01

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.00x
Working Capital Turnover Ttm:0.01x

Receivables Management (2)

Receivables Turnover Ttm:7.54x
Days Sales Outstanding Ttm:48.44

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:3,741.93
Cash Conversion Cycle:-4,692.49
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$74.69M

Damodaran Growth Analysis (2)

Reinvestment Rate:-2.6%
Fundamental Growth Rate (g):1.8%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):-50.0%
Net Income Growth Rate (Linear):32.9%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:RNAC
Company Name:Cartesian Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:29.47M
Shares Outstanding Basic:29.47M
Shares Outstanding Diluted:29.86M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-21 16:28:19 UTC
Data Timestamp:2026-08-18T21:53:17.321423
Scroll to Top